thrombogenicity testing in the 21 st century
play

Thrombogenicity Testing in the 21 st Century: Time for Alternative Strategies for Medical Devices? Michael F. Wolf Scientist and Technical Fellow, Medtronic Inc. Convenor, ISO/TC194 WG9, ISO10993 Part 4: Effects on Blood Public Workshop:

0 downloads 3 Views 5,38 MB Size Report
  1. Thrombogenicity Testing in the 21 st Century: Time for Alternative Strategies for Medical Devices? Michael F. Wolf Scientist and Technical Fellow, Medtronic Inc. Convenor, ISO/TC194 WG9, ISO10993 Part 4: Effects on Blood Public Workshop: Methods for Thrombogenicity Testing April 14, 2014, FDA White Oak Campus

  2. National Research Council. Toxicity Testing in the 21st Century: A Vision and a Strategy . Washington, DC: The National Academies Press, 2007

  3. BLOOD 55% Fluid Elements • Plasma (91% H 2 O) • 7% dissolved proteins  55% albumin  45% globulins  7% fibrinogen, trace proteins • 2% other stuff 45% Formed Elements • RBCs 5,000,000/µL • Platelets 300,000/µL • WBCs 7,000/µL Medical device material surface

  4. Contact Activation (intrinsic) Pathway Tissue Factor (extrinsic) Pathway Damaged Vessel Wall Biomaterial Surface Trauma TF XII XIIa PI K VIII IIa XI XIa VIIa VII Ca K Tissue factor (TF, III) IX IXa VIIIa IXa • VIIIa VIIa•TF K X X Xa Fibrinogen AT Va (I) K Common Thrombin Prothrombin + F1.2 Pathway IIa (T, IIa) (II) AT Fibrin + FPA V Ca (Ia) XIII Antithrombin (AT) XIIIa IIa T • AT Cross-linked Fibrin Protein Ca (TAT) Visual or SEM Protein S IIa Protein C Thrombosis and +Thrombomodulin the Coagulation Cascade

  5. 5 | MDT Confidential

  6. Presentation Outline 1. Background: Where are we today? 2. Background: Virchow’s Triad, and Quintet 3. NAVI Model: Method; Pros and Cons 4. Example methods for medical device/material in vitro thrombogenicity testing using small-volume (3.0 mL) models of human blood

  7. Testing for Medical Device/Material Thrombogenicity Today In vivo animal study In vivo tests

  8. Testing for Medical Device/Material Thrombogenicity Today hemolysis In vivo animal study In vitro tests others others? In vivo tests NAVI AVI

  9. Testing for Medical Device/Material Thrombogenicity … Time for Alternative In Vitro Strategies? In vivo animal Chandler-loop study models Test tube models others In vitro In vivo tests tests Closed loop CPB models NAVI AVI Other models

  10. Virchow’s Triad (1800s - early 1900s) key elements of thrombosis Stasis of blood flow Endothelial injury Hypercoagulability Rudolf Virchow

  11. Virchow’s Triad (Venn diagram – 21 st century) Stasis of blood flow Hyper- Donor Endothelial coagulability Endothelial variability injury injury

  12. Virchow’s Quintet (Pentagon) ….for medical devices Stasis of blood flow Endothelial Donor injury variability Anticoagulants Medical device/ biomaterial Biomaterial Surface Anticoagulants

  13. Virchow’s Quintet – NAVI Model Stasis of blood flow Endothelial injury Donor variability Medical device/material

  14. Virchow’s Quintet – NAVI Model Stasis of blood flow Endothelial injury Donor variability Medical device/material Anticoagulants Anticoagulants

  15. Virchow’s Quintet – In vitro models Blood flow Endothelial injury Donor variability Thrombin generation: phenotypic quantitation, KE Brummel-Ziedens, RL Pouliot, KG Mann, J of Thromb. and Hemost., 2, 281-288, 2003 Medical Anticoagulants device/ biomaterial Anticoagulants

  16. NAVI* Model: Method; Pros and Cons *NAVI = non-anticoagulated venous implant model:

  17. NAVI* Model: Method *NAVI = non-anticoagulated venous implant model: 1 3 2 4 NAVI (and AVI) model variants: 1 = femoral vein 2 = jugular vein 3 = IVC/SVC 4 = IVC-AA

  18. NAVI* Model: Pros *NAVI = non-anticoagulated venous implant model: • Non-thrombogenic coating investigations Heparin Active sequence Polyamine Hydrogel layer Silane layer Biomaterial

  19. NAVI* Model: Pros *NAVI = non-anticoagulated venous implant model: • Non-thrombogenic coating investigations

  20. NAVI* Model: Pros *NAVI = non-anticoagulated venous implant model: • Non-thrombogenic coating investigations Individual test Inner Teflon segments sleeve connectors Proximal Distal Mid

  21. NAVI* Model: Pros *NAVI = non-anticoagulated venous implant model: • Non-thrombogenic coating investigations Individual test Inner Teflon segments sleeve connectors Proximal Distal Mid

  22. NAVI* Model: Pros *NAVI = non-anticoagulated venous implant model: • Non-thrombogenic coating investigations • Investigations on thrombus formation

  23. NAVI* Model: Cons *NAVI = non-anticoagulated venous implant model: • Scoring method variability Score Thrombus Formation Score Description (typical) 0 No significant thrombosis (very small clot acceptable at insertion) 1 Minimal thrombosis, one location. 2 Minimal thrombosis, multiple locations. 3 Significant thrombosis, ≤ ½ the length of the implant, vessel patent. 4 Significant thrombosis, > ½ the length of the implant, vessel patent. 5 Vessel completely occluded. score ≥ 3 is considered failing / ‘not meeting the requirements of the protocol’

  24. NAVI* Model: Cons *NAVI = non-anticoagulated venous implant model: • Scoring method variability Score Thrombus Formation Score Description (typical) 0 No significant thrombosis (very small clot acceptable at insertion) 1 Minimal thrombosis, one location. 2 Minimal thrombosis, multiple locations. 3 Significant thrombosis, ≤ ½ the length of the implant, vessel patent. 4 Significant thrombosis, > ½ the length of the implant, vessel patent. 5 Vessel completely occluded.

  25. NAVI* Model: Cons *NAVI = non-anticoagulated venous implant model: • Scoring method variability Score Thrombus Formation Score Description (typical) 0 No significant thrombosis (very small clot acceptable at insertion) 1 Minimal thrombosis, one location. 2 Minimal thrombosis, multiple locations. 3 Significant thrombosis, ≤ ½ the length of the implant, vessel patent. 4 Significant thrombosis, > ½ the length of the implant, vessel patent. 5 Vessel completely occluded. VS.

  26. NAVI* Model: Cons *NAVI = non-anticoagulated venous implant model: • Scoring method variability Factors that influence NAVI score*:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP)  Evaluator expertise (EE) *M. F. Wolf and J. M. Anderson, Practical approach to blood compatibility assessments: general considerations and standards, in Biocompatibility and performance of medical devices, edited by Jean-Pierre Boutrand, Woodhead Publishing Ltd, (2012).

  27. Factors that influence NAVI score:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP)  Evaluator expertise (EE) B A Femoral, Jugular, IVC/SCV(?), AA(?)

  28. Factors that influence NAVI score:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP)  Evaluator expertise (EE)

  29. Factors that influence NAVI score:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP)  Evaluator expertise (EE)

  30. Factors that influence NAVI score:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP)  Evaluator expertise (EE)

  31. Factors that influence NAVI score:  The implant position (P)  The implant technique (IT)  The extent of device-vessel wall contact (tissue damage, TD)  Time/incubation period (IP)  The explant technique (ET)  The material/material surface (M)  Non-thromboadherent materials get labeled non-thrombogenic (non-thromboadherent, nTA)  The recipient/subject thrombotic potential (TP)  Statistical power (SP) L L L R L R R R  Evaluator expertise (EE) Incubation = 1 hour Incubation = 4 hours

Recommend Documents


possibilities of thrombogenicity testing by in vitro
Possibilities of Thrombogenicity

Blood compatibility and biomarker detection Possibilities of Thrombogenicity

toxicity testing in the 21 st century a vision and
Toxicity Testing in the 21 st Century:

Toxicity Testing in the 21 st Century: A Vision and Strategy Committee on

thrombogenicity on surface modified fd
Thrombogenicity on Surface Modified FD

OCT Evidence of Reduced Thrombogenicity on Surface Modified FD Matthew

alternative interventional surgical methods for the in
Alternative Interventional/Surgical

Alternative Interventional/Surgical Methods for the in-vivo Thrombogenicity

dose response evaluation using a combined parametric non
Dose-response evaluation using a

Dose-response evaluation using a combined parametric/non-parametric approach

distribution testing
Distribution testing in the 21 1/2 th

Distribution testing in the 21 1/2 th century Ryan ODonnell Carnegie Mellon

ppdc work group on 21st century toxicology new integrated
PPDC Work Group on 21st Century

PPDC Work Group on 21st Century Toxicology/New Integrated Testing Strategies

the foundations of 19 th century literature
The Foundations of 19 th Century

The Foundations of 19 th Century Literature are, not surprisingly, in the 18

testing
Testing Terminology System testing

Outline Testing Terminology System testing Types of errors Function

chapter 1
Chapter 1 Fundamentals of testing 1.

Chapter 1 Fundamentals of testing 1. Why is testing necessary? 2. What is

blackpool hospital trust
Blackpool Hospital Trust Sean OBrien

ADAS Referral Site Anticoagulation Dosing Advisory Service Blackpool Hospital

lethal and non lethal prairie dog management
Lethal and Non-Lethal Prairie Dog

Lethal and Non-Lethal Prairie Dog Management Slade Franklin Weed and Pest

an inpatient perspective on the joint commission national
An Inpatient Perspective on the Joint

An Inpatient Perspective on the Joint Commission National Patient Safety

provider
PROVIDER Special Projects, UPDATE

Madhury (Didi) Ray, MD, MPH Critical Care Planning Lead NYC Department of

medication reconciliation and reducing adverse drug events
Medication Reconciliation and Reducing

Medication Reconciliation and Reducing Adverse Drug Events Regional Learning

a 51 year old male 3 weeks s p tka with a swollen knee
A 51-Year-Old Male, 3 weeks s/p TKA

A 51-Year-Old Male, 3 weeks s/p TKA with a Swollen Knee and Calf: Time to

high alert medications reducing patient harm
High Alert Medications: Reducing

High Alert Medications: Reducing Patient Harm Tennessee Center for Patient

special considerations
Special considerations A LEO Pharma

Anticoagulation in active cancer: Special considerations A LEO Pharma

the case for change
The Case for Change Nina Muscillo

The Case for Change Nina Muscillo Manager Medication Safety Clinical

a pooled analysis of the einstein dvt
A Pooled Analysis of the EINSTEIN DVT

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A

deep vein thrombosis and pulmonary embolism diagnosis and
Deep Vein Thrombosis and Pulmonary

Deep Vein Thrombosis and Pulmonary Embolism: Diagnosis and Management in the

inhibition under flow
inhibition under flow SHANNON BRIDE

A mathematical model of surface-mediated enzyme inhibition under flow